Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers : Real-World Evidence From the BECOME Study
Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Lucas, Christian (Hôpital Salengro)
Watson, David P. B. (Hamilton Medical Group)
Gaul, Charly (Migraine and Headache Clinic Königstein)
Ramsden, Emma (Novartis Pharma AG)
Ritter, Shannon (Novartis Pharmaceuticals Corporation)
Martelletti, Paolo (Regional Referral Headache Center, Sant'Andrea Hospital)
Snellman, Josefin (Novartis Pharma AG)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Migraine is consistently ranked as one of the most disabling neurological conditions in the world, often causing a substantial impairment of daily activities and quality of life. It also carries a high economic burden of direct and indirect healthcare costs. Patients with difficult-to-treat migraine often cycle through different preventive therapies, but real-world prospective evidence describing the burden of migraine in patients with prior preventive treatment failure (PPTF) in Europe is limited. In BECOME, we aimed to characterize and assess the prevalence and burden of migraine in patients with PPTF attending specialist headache centers in Europe and Israel. Furthermore, we assessed this burden in pre-specified subgroups based on the frequency of monthly migraine days (MMD) and number of PPTFs. BECOME was a prospective, non-interventional study conducted in two concurrent parts across 17 countries in Europe and Israel. In part 1, patients visiting the centers over a 3-month period were screened for frequency of PPTF, MMD, and other characteristics. In part 2, patients from part 1 with ≥ 1 PPTF and ≥ 4 MMD were enrolled, and impact of migraine on patient-reported outcomes, and healthcare resource utilization (HRU) were examined. In part 1 (n = 20,837), 62. 2% of patients reported ≥ 1 PPTF. In part 2 (n = 2419), 15. 3% of patients reported ≥ 4 PPTF. In part 2, the migraine burden measured by the EuroQoL 5 dimensions 5 level (EQ-5D-5L) questionnaire indicated an impact of at least moderate severity in performing usual activities in 26. 5% of patients, pain/discomfort in 51. 2%, and 26. 1% reported being at least moderately anxious/depressed. Most patients reported a severe impact on daily activities and disability due to migraine. Abnormal Hospital Anxiety and Depression subscale scores of ≥ 11 were observed in 29% (anxiety) and 19. 8% (depression) of the population. In part 2, analysis of HRU showed 21. 2% patients visited an emergency department and 8. 4% were hospitalized for headache/migraine in the past year. This study provides real-world evidence of the high personal, social, and HRU burden of migraine in Europe and Israel. The online version contains supplementary material available at 10. 1007/s40122-021-00331-3.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Burden ; Healthcare resource ; Migraine ; Patient-reported outcomes ; Treatment failure ; Work productivity
Publicat a:	Pain and Therapy, Vol. 10 (october 2021) , p. 1691-1708, ISSN 2193-651X

DOI: 10.1007/s40122-021-00331-3
PMID: 34643891

18 p, 1.1 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats